Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America.

Trial Profile

Efficacy and Safety of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs CYD TDV (Primary)
  • Indications Dengue
  • Focus Registrational; Therapeutic Use
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 14 Jul 2016 Pooled results (n=3736) of two phase III trial (NCT01373281, NCT01374516) published in the Journal of Infectious Diseases
    • 13 Oct 2015 Results of this and other two trials (see profile 200702 and 41674) published in the Vaccine
    • 11 Sep 2014 Full results will be presented at the the American Society of Tropical Medicine and Hygiene (ASTMH) Meeting in November 2014.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top